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Abstract
Background:  Increasing evidence incriminates bacteria, especially Mycoplasma fermentans, as
possible arthritogenic agents in humans. The purpose of this study was to investigate M. fermentans
in the bloodstream of patients with rheumatoid arthritis.
Methods: Two hundred and nineteen blood samples from patients with rheumatoid arthritis,
systemic lupus erythematosus, antiphospholipid syndrome, and healthy individuals were screened
by bacterial culture and direct PCR in order to detect mycoplasmas; IgM and IgG against M.
fermentans  PG18 were also detected by ELISA and Immunoblotting assays in patients with
rheumatoid arthritis and healthy individuals.
Results: Blood samples from patients with antiphospholipid syndrome and healthy individuals
were negative for mycoplasma by culture or direct PCR. In blood samples from patients with
systemic lupus erythematosus were detected by direct PCR M. fermentans in 2/50 (2%), M. hominis
in 2/50 (2%) and U. urealyticum in 1/50 (0.5%). In patients with RA M. fermentans was detected by
culture in 13/87 blood samples and in 13/87 by direct PCR, however, there was only concordance
between culture and direct PCR in six samples, so M. fermentans was detected in 20/87(23%) of the
blood samples from patients with RA by either culture or PCR. Antibody-specific ELISA assay to
M. fermentans PG18 was done, IgM was detected in sera from 40/87 patients with RA and in sera
of 7/67 control individuals, IgG was detected in sera from 48/87 RA patients and in sera from 7/67
healthy individuals. Antibody-specific immunoblotting to M. fermentans PG18 showed IgM in sera
from 35/87 patients with RA and in sera from 4/67 healthy individuals, IgG was detected in sera
from 34/87 patients and in sera from 5/67 healthy individuals.
Conclusion: Our findings show that only M. fermentans produce bacteremia in a high percentage
of patients with RA. This finding is similar to those reported in the literature. IgM and IgG against
M. fermentans PG18 were more frequent in patients with RA than healthy individuals.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease, which results from a complex interplay of factors
both at the systemic level and at the site of inflammation
[1].
Rheumatoid arthritis affects about 1.5% of the world pop-
ulation and occurs more frequently in women than in
men (2.5:1) [2,3]. Although the immune response plays
an important role in RA, the aetiology is unknown. There
are hypotheses which suggest that bacterial agents play an
important role in the onset of the disease, but their causa-
tive link with RA remains controversial, because the stud-
ies have not established a strong enough association [4-6].
Mycoplasmas are a major cause of acute and chronic
arthritis in animals and can induce arthritis in animal
experimental models [7-9]. Mycoplasmas have been con-
sidered possible arthritogenic agents for humans since the
1960's when mycoplasmas were isolated from arthritic
joints of animals, especially Mycoplasma fermentans, which
was isolated from synovial fluids (SF) [10]. There is
increasing evidence to suggest that mycoplasmas may play
a role in RA [11-13]. The other mycoplasmas that are less
frequently involved in human RA are: M. pneumoniae, M.
hominis, M. genitalium, M. salivarium, M. orale, and Urea-
plasma urealyticum [13]. The purpose of this study was to
investigate M. fermentans in the bloodstream of patients
with RA.
Methods
Subjects
One hundred and fifty two patients who attended the
Rheumatology Service of the Hospital Manuel Avila
Camacho del Instituto Mexicano del Seguro Social in Pue-
bla, México were included in the study. A rheumatologist
examined the patients and all fulfilled the American Col-
lege of Rheumatology criteria. The patients' ages ranged
between 25 and 79 yr. All patients with RA were in the
acute phase of the disease and had not been under antibi-
otic treatments for at least six weeks before the sample was
taken.
Sixty-seven individuals without RA, systemic lupus ery-
thematosus (SLE), antiphospholipid syndrome (APS) or
infectious disease were included in the study as healthy
individuals, since in several cases of these diseases an
inflammatory response in the joint is observed. Ages in
the healthy individuals ranged between 20 and 60 yr. All
healthy individuals were not under antibiotic or other
drugs treatment. The ethics committee of the Hospital
Manuel Avila Camacho del Instituto Mexicano del Seguro
Social approved this study and informed patient consent
was obtained.
Specimens
Peripheral whole blood samples from patients and
healthy individuals were collected in order to detect myc-
oplasmas by culture and direct PCR. Antibodies specific to
M. fermentans were also investigated. Blood samples,
which were collected in citrate-containing or non antico-
agulant tubes, were stored at -20°C until use.
Mycoplasmal culture
One hundred microliters of plasma of patients and
healthy individuals were dip-inoculated in 900 μL of three
different media: SP4 medium with glucose, SP4 medium
with urea and SP4 medium with arginine, in order to iso-
late fermentative mycoplasmas, U. Urealyticum and  M.
hominis respectively. An SP4 tube with each media was
incubated as control. Three serial ten-fold dilutions were
incubated at 37°C until the indicator phenol red changed
to yellow for fermentative mycoplasmas or red to non-fer-
mentative, which indicate mycoplasma growth, on the
other hand, cultures were considered negative when the
indicator did not change after 30 days for M. pneumoniae
and M. fermentans, 4 days for M. hominis and U. urealyti-
cum. Control cultures were prepared as follows: one hun-
dred microliters of M. fermentans PG18, M. pneumoniae
Eaton strain, M. hominis, M. penetrans GTU and U. urealyti-
cum were dip-inoculated into 900 μL of plasma, and three
serial ten-fold dilutions were done into SP4 media with
glucose, urea or arginine and incubated at 37°C for 48
hours or until the indicator changed showing myco-
plasma growth. Likewise, one hundred microliters of each
reference strains were dip-inoculated into 900 μL of the
SP4 media with the respective substrate. Dilutions are rec-
ommended when tissues or corporal fluids are cultivated,
because some inhibitory substances for mycoplasmas
may be present. Positive mycoplasma cultures were con-
firmed using the PCR technique. All the blood samples
were directly cultured on blood agar plates to detect any
aerobes or aerobic facultative bacteria.
DNA extraction from blood samples
Red blood cells (2.5 ml) were lysed with nanopure water
(10 ml) at room temperature for 10 min and centrifuged
at 3,000 × g for 10 min. The pellet containing white cells
was treated as follow: Triton X-100 (1%, 10 ml) was
added and mixed gently for 5 min. After centrifugation at
3,000 × g for 10 min, SDS (1%, 10 ml) was added and
mixed gently for 10 min, NaCl (0.1 M, 10 ml) was added
for 10 min followed by the addition of 10 ml of cold eth-
anol. After centrifugation at 10,000 × g for 10 min, the
supernatant was discarded and the DNA was recovered in
500 μL of nanopure water and stored at -20°C. DNA was
also extracted from a 1.4 ml whole blood sample seeded
with 100 μL of M. fermentans PG18 for use as a positive
control sample.BMC Musculoskeletal Disorders 2009, 10:97 http://www.biomedcentral.com/1471-2474/10/97
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DNA extraction from mycoplasmal cultures
DNA was extracted from Mycoplasma-positive cultures as
follows: 1.5 ml of culture was centrifuged at 12,000 × g for
20 min, the supernatant was discarded and the pellet was
suspended in 100 μL of a solution containing 10 mM Tris-
HCl pH 8.3, 100 mM KCl, 2.5 mM MgCl2, 1% Tween-20,
1% Triton X-100 and 0.5 mg/ml of proteinase K. Samples
were heated at 60°C for 60 min and immediately brought
to 90°C for 10 min, then placed in an ice bath for 20 min
and stored at -20°C [14].
PCR assays
PCR detection of Mycoplasma sp. DNA using 16 s RNA
gene primers AR1 and AR2 was performed according to
Shidu et al. [14]. The primers used to identify species are
shown in Additional file 1[15-19]. Amplification was per-
formed in a total volume of 50 μL containing 50 mM KCl,
1.5 mM MgCl2, 10 mM Tri-HCl (pH 8.3), 0.2 mM of each
dNTP (Amersham Pharmacia Biotech, USA) and 1 unit of
ampliTaq polymerase (Gibco, BRL, USA). The sample to
be analysed was always added last. A diluted lysate of M.
fermentans PG18 or M. pneumoniae (Eaton strain) or M.
penetrans GTU-54 or M. hominis or U. urealyticum corre-
sponding to 100 colour-changing units and sterile water
were used as positive and negative controls, respectively.
Amplification consisted of a 10-min thermal delay step at
95°C, followed by 40 cycles comprising a 20 s denatura-
tion step at 95°C, a 1-min annealing step at 62°C, a 1-min
elongation step at 72°C, and a final 4-min elongation step
at 72°C PCRS were performed with an automated ther-
mocycler (MJ Research, Watertown, MA.). PCR products
were analysed by 2% agarose gels electrophoresis and
ethidium bromide staining [14].
Antibody-specific ELISA assay
The antibodies IgM and IgG to M. fermentans PG18 in sera
were measured by ELISA using M. fermentans PG18 whole
cells adjusted to an OD 600 = 1 and performed as
described by Horowitz et al., 1995 [20]. Samples with
absorbance equal to or higher than the mean of the con-
trol group plus three standard deviations for IgM and IgG
were considered positive.
Antibody-specific immunoblotting assay
The antigen used was M. fermentans PG18 whole cells
adjusted to an OD 600 = 1 and 750 μL of this solution was
mixed with 250 μL of sample buffer 4×(40% glycerol, 240
mM Tris/HCl pH 6.8, 0.04% bromophenol blue, 5% beta-
mercaptoethanol) and boiled during ten minutes. Immu-
noblotting according to Horowitz et al. 1998 [21] was
applied to detect IgM and IgG specific to M. fermentans
PG18. The antibodies were detected by incubating 2 nitro-
cellulose (NC) strips in each patient's serum diluted 1:100
in PBS at 37°C for 2 h. Peroxidase-conjugates anti-human
IgM or IgG were diluted 1:5000 in PBS and one strip was
used in order to detect every one of the antibody isotypes.
A rabbit was immunized with M. fermentans PG18 and the
serum was used as positive control (line 11, figure 1). Per-
oxidase substrate was prepared according to manufacturer
(Sigma Co.) and the bound peroxidase activity was visual-
ized using the incubation of the NC strips for 5 to 20 min
at room temperature. The enzymatic reaction was stopped
and stabilized by washing the NC strips in a solution con-
taining 13 ml of dioctyl sodium sulfosuccinate-ethanol in
37 ml of water.
Statistical analysis
Chi squared test was done in order to compare the pres-
ence of antibodies against M. fermentans in patients and
healthy individuals.
Results
Patients
Eighty seven patients with RA, 50 patients with SLE and 15
patients with APS were included in the study; all of them
had varying times of disease, duration ranging from 2–25
years. All patients with autoimmune diseases were receiv-
ing weekly immunosuppressive therapy (50% receiving
prednisone at 5–10 mg and/or methotrexate at 5–10 mg).
All patients were receiving therapy with non-steroidal,
anti-inflammatory drugs. Thirty percent of the patients
had a history of recurrent respiratory or genitourinary
tract infections, but at the time of specimen collection
there were no signs of infectious disease.
Mycoplasmal culture
All of the blood samples from patients with SLE, APS and
healthy individuals were negative for mycoplasma by cul-
ture. Among the 87 peripheral blood samples from
patients with RA, thirteen were considered culture-posi-
tive for M. fermentans because they changed the colour
indicator of the media and the pure culture was then iden-
tified by PCR (Additional file 2).
Detection of Mycoplasma DNA by Direct PCR
AR1 and AR2 genus-specific primers, which amplify a 16
s RNA gene fragment, were used to detect mycoplasmas in
peripheral blood samples. Mycoplasma spp sequence was
amplified in 13/87 samples from patients with RA and 5/
50 samples from patients with SLE. All the peripheral
blood samples from APS patients and healthy individuals
were negative. Species-specific PCR primers were then
used to determine which mycoplasmas were present. All
samples from RA patients in which Mycoplasma spp DNA
was amplified were positive for M. fermentans DNA, in
blood samples from patients with SLE were detected by
direct PCR to M. fermentans in 2/50 (2%), M. hominis in 2/
50 (2%) and U. urealyticum in 1/50 (0.5%). Respect to the
identification of M. fermentans in patients with RA, there
was only concordance between culture and direct PCR inBMC Musculoskeletal Disorders 2009, 10:97 http://www.biomedcentral.com/1471-2474/10/97
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6 patients, so we identified M. fermentans in 20/87 (23%)
patients with RA (Additional file 2).
Antibody-specific ELISA assay
IgM and IgG against M. fermentans PG18 were measured
by ELISA. A threshold level above which samples were
deemed positive was determined using a cut-off value
generated from results from the control population. IgM
against M. fermentans PG18 was detected in sera from 40/
87 patients with RA and in sera of 7/67 healthy individu-
als. X2 was calculated and association between the pres-
ence of IgM antibodies against M. fermentans PG18 and
RA patients (p < .01). IgG was detected in sera from 48/87
RA patients and in sera from 7/67 healthy individuals.
There was association between the absence of antibodies
against M. fermentans PG18 and healthy individuals (p <
0.1) using X2. A higher percentage of patients than healthy
individuals had antibodies against M. fermentans PG18
(Additional file 3).
Antibody-specific immunoblotting assay
IgM-specific to M. fermentans PG18 was detected in sera
from 35/87 patients with RA and in sera from 4/67
healthy individuals. IgG was detected in sera from 34/87
patients and in sera from 5/67 healthy individuals. Figure
1 shows representative results of immunobloting assay,
IgM and IgG were detected to P70 and p48. There was a
significant difference. X2 was calculated (p < 0.1) (Addi-
tional file 3).
Discussion
Infectious agents such as viruses, bacteria, and bacterial
components have been hypothesized to play some role in
the pathology of RA and other autoimmune diseases
based on clinical and pathological findings in humans
and animals [22-24]. However, this hypothesis remains
unproven. Hernández et al. (1998) studied the recurrence
and severity of infections in Mexican patients with RA and
found that 48.7% of the patients suffered from infections
related to treatment with steroids and methotrexate [25].
In this study we examined blood samples from RA, SLE,
and APS patients for aerobic, aerobic facultative bacteria
and mycoplasmas in particular, through culture, PCR, and
immunological assays. Although all samples were nega-
tive for aerobic or aerobic facultative bacteria, 30% of the
patients had a history of recurrent upper respiratory and
genitourinary tract infections, 50% were being treated
with prednisone and/or MTX, and 100% were being
treated with nonsteroidal antinflammatory drugs. These
findings are consistent with a role for infectious agents in
RA. Mycoplasmas are putative agents in RA because they
can produce arthritis in animals [26] and have also been
detected in patients with RA [27] and other inflammatory
arthritides [28]. However, results have been poorly repro-
duced, in part because of the difficulties of working with
mycoplasmas. Since mycoplasmas are fastidious bacteria
that are difficult to culture and identify and also may suf-
fer phenotypic changes in culture, culture techniques and
serological assays are not reliable diagnostic tests for myc-
oplasmal infection. Serology provides evidence of host
contact with mycoplasmas, but does not provide evidence
of the bacteria in the host. PCR techniques allow sensitive
and specific detection of mycoplasmal DNA in various
biological samples [29,30], but gives no information
about the viable bacteria. To detect whether there is a
causal relationship of microorganisms with arthritis it is
important the viable bacteria as well as the immune
response to the bacteria. That is why we used several tech-
niques to diagnose mycoplasmal infection. In order to
obtain reproducible results, we used standard techniques
reported for isolation and PCR identification of mycoplas-
mas and all the risk factors of contamination were
avoided.
The AR1 and AR2 primers have been reported as specific
to the Mycoplasma  genus (they do not cross-react with
other bacteria) and can amplify 16 s RNA gene nucleotide
sequences of 30 different species [14]. Using these primers
and species-specific primers, we detected M. fermentans in
23% of patients with RA and in 2% of patients with SLE,
but did not detect it in patients with APS or in healthy
individuals.
M. fermentans has been previously detected in patients
with RA and inflammatory diseases. Schaeverbeke et al.
(1997) detected M. fermentans in two patients with RA
Antibodies-specific to P70 and P48 were detected Figure 1
Antibodies-specific to P70 and P48 were detected. 
Line MW molecular weights; line 1 M. fermentans PG18 anti-
gens extracted by heat; line 2, 4, 6, 8 IgM detection; line 3, 5, 
7 IgG detection; line 9, 10 negative serum from healthy indi-
viduals; line 11 positive serum from an immunized rabbit with 
M. fermentans PG18.BMC Musculoskeletal Disorders 2009, 10:97 http://www.biomedcentral.com/1471-2474/10/97
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and in one patient with a different inflammatory arthritis.
They also reported the isolation of M. hominis, M. salivar-
ium, M. orale, and U. urealyticum from SF and did not find
concordance between culture and PCR [13]. Horowitz et
al. (2000) detected M. fermentans DNA in SF from 17.6%
of patients with RA and in one patient with undefined
arthritis, but it was not detected by culture in any of these
patients and they did not detect M. fermentans in other
inflammatory or non-inflammatory arthropathies [31].
Gilroy et al. (2001) detected M. fermentans DNA in the SF
of 17% of patients with RA and in 21% of patients with
seronegative arthritis, and they did not detect it in patients
with other arthropathies [11]. In contrast, Johnson et al.
(2000) and Hoffman et al. (1997) reported higher per-
centages of detection of DNA of M. fermentans by PCR.
The former reported M. fermentans in 31/34 patients with
RA, and in 9/11 patients with non-rheumatoid inflamma-
tory arthritis, and it was not isolated in patients with oste-
oarthritis. The latter did not detect M. fermentans in SF or
tissues and did not use culture procedures [12,32]. Haier
et al. (1999) identified M. fermentans, M. pneumoniae, M.
hominis  and  M. penetrans by PCR in leucocytes from
patients with RA [27]. In contrast, in this study we did not
detect M. pneumoniae or M. penetrans. M. hominis and U.
urealyticum were only identified by PCR in patients with
SLE. Johnson et al. (2007) found by a very sensitive PCR a
conserved mycoplasmal 16 S RNA of M. pneumoniae in the
SF from patients with RA, osteoarthritis and nonrheuma-
toid inflammatory arthritis and it was not found in the SF
from people with knee injuries or undergoing surgery for
knee replacement [33].
Immune and inflammatory responses can be triggered or
exacerbated by many factors including infectious agents.
Aerobic and anaerobic bacteria, as well as viruses and
mycoplasmas, have been considered as important agents
in RA. Mycoplasmas have the ability to induce a broad
range of inflammatory and immunological events. They
are able to induce cytokine production and also activate
macrophages, B and T lymphocytes. In this study we
investigated whether antibodies against M. fermentans
PG18 were present in sera from patients with RA and
healthy individuals. Our results are similar to those
reported by Horowitz et al. (2000), who detected antibod-
ies against M. fermentans in 50% of patients with RA and
20% of patients with other arthritis; however there are dif-
ferences respect to M. fermentans peptides detected, while
Horowitz et al. detected antibodies to p107, p48 and p29,
we reported antibodies to p70 and p48, the differences
probably are due to the different strains and the technique
used for the antigen extraction [31]. In contrast Hoffman
et al. (1997) found antibodies against M. hominis in 55%
of patients with RA and 88% juvenile RA patients and they
also detect antibodies against this microorganism in
patients with other inflammatory disease and controls
[32]. Ramírez et al. (2005) performed a case-control study
in which they show a statistical difference when they com-
pare the presence of antibodies against M. pneumoniae in
patients with RA and controls [34]. In our study, 20 out of
87 RA patients showed evidence of infection with M. fer-
mentans. Thirteen patients had persistent infection with
M. fermentans as evidenced by cultivable bacteria in the
blood. All but two of these thirteen displayed an antibody
response to M. fermentans. These results suggest that viable
M. fermentans in blood of patients with RA is common,
even though the role of bacteria is not known. In the other
hand, it will be important to do studies in order to detect
antibodies against M. fermentans glycolipid-antigen in
patients with RA and other inflammatory arthritides, since
Kawahito et al. (2008) detected to GGPL-III in 38.1% of
RA patient's tissues [35].
There is a hypothesis that bacteria may trigger arthritis,
and two models are often considered. One model postu-
lates that arthritis is promoted by inflammation due to a
chronic infection characterized by the long term presence
of low levels of bacteria. The other postulates a "hit and
run" phenomenon in which bacteria infect a joint for only
a short period of time before being cleared [36], but initi-
ate a cascade of inflammatory events while there, both
nonspecific and specific responses that lead to inflamma-
tion and arthritis [37]. M. fermentans, which is frequently
isolated from joints, may fit into the "hit and run" class.
The main contribution of this study is that M. fermentans
bacteremia was present in a significant number of patients
with RA, supporting the idea that M. fermentans is a possi-
ble agent to consider in the pathology of RA. These results,
and those of previous studies that also detected M. fermen-
tans in RA patients, suggest that patients with RA have
been exposed to M. fermentans, and that a high percentage
of patients develop a systemic mycoplasmal infec-
tion[13,27,31], and the contradictory results on his isola-
tion or identification are in part, because this mycoplasma
may not be permanently in SF or tissues due to passive
carriage or ubiquitous[31], since it has been found in
pharynx, saliva peripheral mononuclear cells[38],
another fact that support that M. fermentans can be associ-
ated with RA, was the study of Rivera et al. in an animal
model, in which they showed that when this microorgan-
ism is inoculated in the trachea it can reach the joint [9].
The role of M. fermentans in initiating or perpetuating syn-
ovitis should be explored further, but three hypotheses
can be considered with respect to the role of mycoplasmas
in RA. The first proposes that M. fermentans is a cofactor of
the disease in a genetically susceptible host and its role is
in the induction of the autoimmune response. On the
other hand, the second suggests that RA is produced by
the reach of M. fermentans in the joint and the liberation
of toxic substances or cytokines that produce joint dam-
age [39]. With the same evidence, the third proposes thatBMC Musculoskeletal Disorders 2009, 10:97 http://www.biomedcentral.com/1471-2474/10/97
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patients with RA are frequently under steroid treatment
and steroids may favour systemic infections with M. fer-
mentans.
Since RA has been associated with the presence of autoan-
tibodies including rheumatoid factor, and the role of
microorganisms is still unknown, the other important
role in this disease is the genetic risk. Histocompatibility
antigens (HLA-DR 1/4) in patients with RA have been
studied, motif sequences like QKRAA, QRRAA. RRRAA or
ESRRAL have been implicated in the susceptibility to
develop RA. There are studies that determined the pres-
ence of share epitope in microorganisms[40]. Ebringer et
al. (1992) show cross-reactivity between HLA-DR4 and
Proteus mirabilis haemolysin [41] although in mycoplas-
mas there are not studies about the presence of shared
epitope, it will be important to study this possibility.
Conclusion
Our results are similar to those reported in the literature
regarding the implication of M. fermentans in RA. The
main contribution of our study is that only M. fermentans
produce bacteremia in a higher percentage of patients
with RA. IgM and IgG were detected against p70 and p48
M. ferementans antigens. These findings suggests that M.
fermentans is common in these patients and it may enter
through the respiratory tract and blood could be the
medium to reach joints, where they may induce an
inflammatory or immune response.
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